Effect of epinephrine and insulin resistance on human monocytes obtained from lean and obese healthy participants: A pilot study

Angiology

Volumn 62, Issue 1, 2011, Pages 38-45

  Sarigianni, Maria ^a   Bekiari, Eleni ^a   Tsapas, Apostolos ^a   Konstantinidis, Diamantis ^b   Kaloyianni, Martha ^b   Koliakos, George ^a   Paletas, Konstantinos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

atherosclerosis; epinephrine; insulin resistance; monocytes; obesity

Indexed keywords

ADRENALIN; CARIPORIDE; LAMININ 1; NITRIC OXIDE SYNTHASE; OXIDIZED LOW DENSITY LIPOPROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ACTIN POLYMERIZATION; ADULT; ARTICLE; CELL ADHESION; CELL MIGRATION; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MONOCYTE; OBESITY; PHAGOCYTOSIS; PROTEIN BLOOD LEVEL;

ADOLESCENT; ADULT; EPINEPHRINE; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MONOCYTES; OBESITY; PILOT PROJECTS; THINNESS; YOUNG ADULT;

EID: 78650189780     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319710371616     Document Type: Article

References (58)

1. World Health Organization. Preventing and Managing the Global Epidemic: report of a World Health Organization Consultation on Obesity. Geneva, Switzerland: World Health Organization; 1997.
2. Alpert JS "So, doctor, what's so bad about being fat?" Combating the obesity epidemic in the United States. Am J Med. 2010 ; 123 (1). 1-2.
3. Flegal KM, Carroll MD, Ogden CL, Curtin LR Prevalence and trends in obesity among us adults, 1999-2008. JAMA. 2010 ; 303 (3). 235-241.
4. Athyros VG, Ganotakis ES, Tziomalos K., et al. Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin. 2010 ; 26 (3). 713-719.
5. Ravussin E., Tataranni PA The role of altered sympathetic nervous system activity in the pathogenesis of obesity. Proc Nutr Soc. 1996 ; 55 (3). 793-802.
6. Grassi G., Quarti-Trevano F., Seravalle G., Dell'Oro R., Dubini A., Mancia G. Differential sympathetic activation in muscle and skin neural districts in the metabolic syndrome. Metabolism. 2009 ; 58 (10). 1446-1451.
7. Alvarez GE, Beske SD, Ballard TP, Davy KP Sympathetic neural activation in visceral obesity. Circulation. 2002 ; 106 (20). 2533-2536.
8. Nagae A., Fujita M., Kawarazaki H., Matsui H., Ando K., Fujita T. Sympathoexcitation by oxidative stress in the brain mediates arterial pressure elevation in obesity-induced hypertension. Circulation. 2009 ; 119 (7). 978-986.
9. Yeckel CW, Gulanski B., Zgorski ML, Dziura J., Parish R., Sherwin RS Simple exercise recovery index for sympathetic overactivity is linked to insulin resistance. Med Sci Sports Exerc. 2009 ; 41 (3). 505-515.
10. Straznicky NE, Eikelis N., Lambert EA, Esler MD Mediators of sympathetic activation in metabolic syndrome obesity. Curr Hypertens Rep. 2008 ; 10 (6). 440-447.
11. Zevin S., Saunders S., Gourlay SG, Jacob P., Benowitz NL Cardiovascular effects of carbon monoxide and cigarette smoking. J Am Coll Cardiol. 2001 ; 38 (6). 1633-1638.
12. Bierhaus A., Wolf J., Andrassy M., et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci U S A. 2003 ; 100 (4). 1920-1925.
13. Greeson JM, Lewis JG, Achanzar K., Zimmerman E., Young KH, Suarez EC Stress-induced changes in the expression of monocytic beta2-integrins: the impact of arousal of negative affect and adrenergic responses to the anger recall interview. Brain Behav Immun. 2009 ; 23 (2). 251-256.
14. De Glisezinski I., Larrouy D., Bajzova M., et al. Adrenaline but not noradrenaline is a determinant of exercise-induced lipid mobilization in human subcutaneous adipose tissue. J Physiol. 2009 ; 587 (pt 13). 3393-3404.
15. Tripathy D., Mohanty P., Dhindsa S., et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes. 2003 ; 52 (12). 2882-2887.
16. Mikhailidis DP, Barradas MA, Jeremy JY, Dandona P. Cigarette smoking inhibits prostacyclin formation. Lancet. 1983 ; 2 (8350). 627-628.
17. Jeremy JY, Mikhailidis DP, Dandona P. Simulating the diabetic environment modifies in vitro prostacyclin synthesis. Diabetes. 1983 ; 32 (3). 217-221.
18. Barradas MA, Mikhailidis DP, Dandona P. The effect of non-esterified fatty acids on vascular ADP-degrading enzyme activity. Diabetes Res Clin Pract. 1987 ; 3 (1). 9-19.
19. Ahlquist RP Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor. Am Heart J. 1976 ; 92 (6). 661-664.
20. Jeremy JY, Mikhailidis DP, Dandona P. Adrenergic modulation of vascular prostacyclin (PGI2) secretion. Eur J Pharmacol. 1985 ; 114 (1). 33-40.
21. Sarigianni M., Bekiari E., Tsapas A., et al. Effect of leptin and insulin resistance on properties of human monocytes in lean and obese healthy subjects. Angiology. 2010 ;IN PRESS.
22. Bourikas D., Kaloyianni M., Bougoulia M., Zolota Z., Koliakos G. Modulation of the Na(+)-H(+) antiport activity by adrenaline on erythrocytes from normal and obese individuals. Mol Cell Endocrinol. 2003 ; 205 (1-2). 141-150.
23. Garber AJ, Cryer PE, Santiago JV, et al. The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia in man. J Clin Invest. 1976 ; 58 (1). 7-15.
24. Dimitrov S., Lange T., Born J. Selective mobilization of cytotoxic leukocytes by epinephrine. J Immunol. 2010 ; 184 (1). 503-511.
25. Verdegaal M., Zegveld S., Van Furth R. Heat shock protein 65 induces CD62e, CD106, and CD54 on cultured human endothelial cells and increases their adhesiveness for monocytes and granulocytes. J Immunol. 1996 ; 157 (1). 369-376.
26. Baumgarth M., Beier N., Gericke R. (2-methyl-5-(methylsulfonyl) benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 ; 40 (13). 2017-2034.
27. Itabe H. Oxidized low-density lipoproteins: what is understood and what remains to be clarified. Biol Pharm Bull. 2003 ; 26 (1). 1-9.
28. Stephan ZF, Yurachek EC. Rapid fluorometric assay of LDL receptor activity by DiI-labeled LDL. J Lipid Res. 1993 ; 34 (2). 325-330.
29. Lundberg U. Stress hormones in health and illness: the roles of work and gender. Psychoneuroendocrinology. 2005 ; 30 (10). 1017-1021.
30. Li CY, Chou TC, Lee CH, et al. Adrenaline inhibits lipopolysaccharide- induced macrophage inflammatory protein-1 alpha in human monocytes: the role of beta-adrenergic receptors. Anesth Analg. 2003 ; 96 (2). 518-523.
31. Agarwal SK, Marshall GD Jr. Beta-adrenergic modulation of human type-1/type-2 cytokine balance. J Allergy Clin Immunol. 2000 ; 105 (1 pt 1). 91-98.
32. Folkow B. Neurotrophic effects on the vascular bed. Acta Med Scand Suppl. 1983 ; 672: 95-99.
33. Leineweber K., Aker S., Beilfuss A., et al. Inhibition of Na+/H+exchanger with sabiporide attenuates the downregulation and uncoupling of the myocardial beta-adrenoceptor system in failing rabbit hearts. Br J Pharmacol. 2006 ; 148 (2). 137-146.
34. Schafer M., Schafer C., Michael Piper H., Schluter KD Hypertrophic responsiveness of cardiomyocytes to alpha- or beta-adrenoceptor stimulation requires sodium-proton-exchanger-1 (NHE-1) activation but not cellular alkalization. Eur J Heart Fail. 2002 ; 4 (3). 249-254.
35. Schena M., Mulatero P., Schiavone D., et al. Vasoactive hormones induce nitric oxide synthase mRNA expression and nitric oxide production in human endothelial cells and monocytes. Am J Hypertens. 1999 ; 12 (4 pt 1). 388-397.
36. Diaz-Cruz A., Guinzberg R., Guerra R., et al. Adrenaline stimulates H2O2 generation in liver via NADPH oxidase. Free Radic Res. 2007 ; 41 (6). 663-672.
37. Yasui H., Kubota M., Iguchi K., et al. Membrane trafficking of aquaporin 3 induced by epinephrine. Biochem Biophys Res Commun. 2008 ; 373 (4). 613-617.
38. Srinivasan R., Forman S., Quinlan RA, Ohanian J., Ohanian V. Regulation of contractility by HSP27 and HIC-5 in rat mesenteric small arteries. Am J Physiol Heart Circ Physiol. 2008 ; 294 (2). H961 - H969.
39. Mizuochi Y., Okajima K., Harada N., et al. Carvedilol, a nonselective beta-blocker, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro. Transl Res. 2007 ; 149 (4). 223-230.
40. Friedrich T., Burckhardt G. Inhibition of the rat renal Na+/H+ exchanger by beta-adrenergic antagonists. Biochem Biophys Res Commun. 1991 ; 175 (1). 311-317.
41. Wang P., Zaragoza C., Holman W. Sodium-hydrogen exchange inhibition and beta-blockade additively decrease infarct size. Ann Thorac Surg. 2007 ; 83 (3). 1121-1127.
42. Liang C., Xiaonan L., Xiaojun C., et al. Effect of metoprolol on vulnerable plaque in rabbits by changing shear stress around plaque and reducing inflammation. Eur J Pharmacol. 2009 ; 613 (1-3). 79-85.
43. De Nigris F., Mancini FP, Balestrieri ML, et al. Therapeutic dose of nebivolol, a nitric oxide-releasing beta-blocker, reduces atherosclerosis in cholesterol-fed rabbits. Nitric Oxide. 2008 ; 19 (1). 57-63.
44. Kaye DM, Lefkovits J., Cox H., et al. Regional epinephrine kinetics in human heart failure: evidence for extra-adrenal, non-neural release. Am J Physiol. 1995 ; 269 (1 pt 2). H182 - H188.
45. Esler M., Kaye D. Measurement of sympathetic nervous system activity in heart failure: the role of norepinephrine kinetics. Heart Fail Rev. 2000 ; 5 (1). 17-25.
46. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999 ; 353 (9146). 9-13.
47. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999 ; 353 (9169). 2001-2007.
48. Herman M., Donovan J., Tran M., et al. Use of beta-blockers and effects on heart rate and blood pressure post-acute coronary syndromes: are we on target? Am Heart J. 2009 ; 158 (3). 378-385.
49. Satoh M., Ishikawa Y., Minami Y., Akatsu T., Nakamura M. Eplerenone inhibits tumour necrosis factor alpha shedding process by tumour necrosis factor alpha converting enzyme in monocytes from patients with congestive heart failure. Heart. 2006 ; 92 (7). 979-980.
50. Liuzzo G., Santamaria M., Biasucci LM, et al. Persistent activation of nuclear factor kappa-b signaling pathway in patients with unstable angina and elevated levels of c-reactive protein evidence for a direct proinflammatory effect of azide and lipopolysaccharide-free c-reactive protein on human monocytes via nuclear factor kappa-b activation. J Am Coll Cardiol. 2007 ; 49 (2). 185-194.
51. Brunner S., Kim JO, Methe H. Relation of matrix metalloproteinase-9/ tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease. Am J Cardiol. 2010 ; 105 (4). 429-434.
52. Kunjathoor VV, Febbraio M., Podrez EA, et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem. 2002 ; 277 (51). 49982-49988.
53. Boullier A., Bird DA, Chang MK, et al. Scavenger receptors, oxidized LDL, and atherosclerosis. Ann N Y Acad Sci. 2001 ; 947: 214-222.
54. Konstantinidis D., Paletas K., Koliakos G., Kaloyianni M. Signaling components involved in leptin-induced amplification of the atherosclerosis- related properties of human monocytes. J Vasc Res. 2009 ; 46 (3). 199-208.
55. Mancia G., Bousquet P., Elghozi JL, et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens. 2007 ; 25 (5). 909-920.
56. Paraskevas KI, Liapis CD, Mikhailidis DP Leptin: a promising therapeutic target with pleiotropic action besides body weight regulation. Curr Drug Targets. 2006 ; 7 (6). 761-771.
57. Flaa A., Aksnes TA, Kjeldsen SE, Eide I., Rostrup M. Increased sympathetic reactivity may predict insulin resistance: An 18-year follow-up study. Metabolism. 2008 ; 57 (10). 1422-1427.
58. Dereli D., Ozgen G., Buyukkececi F., Guney E., Yilmaz C. Platelet dysfunction in lean women with polycystic ovary syndrome and association with insulin sensitivity. J Clin Endocrinol Metab. 2003 ; 88 (5). 2263-2268.